Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Kyushu University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Japan register with Kyushu University as lead sponsor. Synced 10 Oct 2026
4Current trials
4Recruiting now
3Drugs in these trials
1Trial register
At a glance

Kyushu University is the lead sponsor of 4 current clinical trials in our Japan register. 4 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Fluorouracil, Pembrolizumab and Trifluridine/Tipiracil. The most-studied condition is Gastric Cancer.

ClinicalTrials.gov trials by status

  • Recruiting4100%

Trials by phase

  • Phase 1/2250%
  • Phase 1250%
01

Clinical trials sponsored by Kyushu University

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
NCT05438459 · ClinicalTrials.gov ↗ · Gastric Cancer, Pancreatic Cancer
Phase 1/2 Recruiting 2022-06 Japan
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
NCT07774975 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa (RP)
Phase 1 Recruiting 2026-10 Japan
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
NCT07738952 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Attack
Phase 1/2 Recruiting 2026-10 Japan
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
NCT05608148 · ClinicalTrials.gov ↗ · Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors
Phase 1 Recruiting 2022-10 Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Kyushu University trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Kyushu University trials

6 conditions
Gastric Cancer1Pancreatic Cancer1Retinitis Pigmentosa (RP)1Neuromyelitis Optica Spectrum Disorder Attack1Refractory/Relapse Neuroblastoma1Pediatric Solid Tumors1
06

Questions about Kyushu University trials

How many clinical trials does Kyushu University sponsor?

Kyushu University is the lead sponsor of 4 current trials on ClinicalTrials.gov in our Japan register, as of the registry sync on 10 October 2026. Completed and withdrawn studies are not counted.

Are Kyushu University trials recruiting?

Yes. 4 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Kyushu University testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Fluorouracil (1), Pembrolizumab (1) and Trifluridine/Tipiracil (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.